Autoimmune phenomena in untreated and treated marginal zone lymphoma

Bibliography

• Jaffe ES, Harris NL, Stein H, World Health Organization classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues. IARC Press; Lyon (France); 2001. p. 1-351
   Google Scholar
• The Non-Hodgkin's lymphoma classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Jardin F. Development of autoimmunity in lymphoma. Expert Rev Clin Immunol 2008;4:247-66
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Cozen W, Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008;15:5150-60
   Web of Science ®Google Scholar
• Ansell P, Simpson J, Lightfoot T, Non-Hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer 17 Sep 2010; [Epub ahead of print]
   PubMedGoogle Scholar
• van de Schans SA, van Spronsen DJ, Hooijkaas H, Excess of autoimmune and chronic inflammatory disorders in patients with lymphoma compared with all cancer patients. A cancer registry-based analysis in the south of Netherlands. Autoimmun Rev 2011;10:228-34
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Coiffier B. MALT lymphoma: sites of presentations, clinical features and staging procedures. In: Zucca E, Bertoni F. editors, MALT lymphomas. Landes Bioscience/Kluwer Academic; Geaorgetown (TX); 2004. p. 60-80
   Google Scholar
• Thieblemont C, Berger F, Dumontet C, Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 pateints analyzed. Blood 2000;95:802-6
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Pedrinis E, Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-95
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F, Stathis A, Marginal Zone Lymphomas. Hematol Oncol Clin N Am 2008;22:883-901
   PubMed Web of Science ®Google Scholar
• Rogerro E, Zucca E, Mainetti C, Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263-8
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Guidoboni M, Ponzoni M, Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-94
   PubMed Web of Science ®Google Scholar
• Lecuit M, Abachin E, Martin, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-48
   PubMed Web of Science ®Google Scholar
• Wohrer S, Troch M, Streubel B, MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia 2007;21:1812-18
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrere F, Bronowiski JP, Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94
   PubMed Web of Science ®Google Scholar
• Berger F, Felman P, Theiblemont C, Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950-6
   PubMed Web of Science ®Google Scholar
• Voinchet H, Etienne G, Ghiringelli CB, Splenic marginal zone lymphoma and autoimminity: report of six cases. Rev Med Interne 2010;31:4-11
   PubMed Web of Science ®Google Scholar
• Guyomard S, Salles G, Coudurier M, Prevalence and pattern of antinuclear autoantibodies in 347 pateints with non-Hodgkin's lymphoma. Br J Haematol 2003;123:90-9
   PubMed Web of Science ®Google Scholar
• Manner H, Jung B, Tonassi L, Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal- zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008;335:394-7
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Voulgarelis M. Update on Sjogren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007;21:989-1010
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Moutsopoulos HM. Lymphoproliferation in autoimmunity and Sjogren's syndrome. Curr Rheumatol Rep 2003;5:317-23
   PubMedGoogle Scholar
• Bozinovic MT, Katic V, Krasic D, Clinical, histopathological and immunohistological study of lymphoid disorders in the parotid gland of patients with Sjogren's syndrome. Vojnosanit Pregl 2009;66:955-60
   PubMed Web of Science ®Google Scholar
• Carbone J, Perez-Fernandez R, Munoz A, Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma. Clin Rev Allergy Immunol 2008;34:80-4
   PubMed Web of Science ®Google Scholar
• Troch M, Woehrer S, Streubel B, Chronic autoimmune thyroiditis (Hashimoto thyroiditis) in patients with MALT lymphoma. Ann Oncol 2008;19:1336-9
   PubMed Web of Science ®Google Scholar
• D'Antonio A, Caleo A, Licci S, A minute focus of extranodal marginal zone B-cell lymphoma arising in Hashimoto thyroiditis diagnosed with PCR after laser capture microdissection: a case report. Thyroid Res 2009;7:9
   Google Scholar
• Serefhanoglu S, Tapan U, Ertenli I, Primary thyroid marginal zone B-cell lymphoma MALT-type in patient with rheumatoid arthritis. Med Oncol 2010;27:826-32
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Feldman P, Callet-Bauchu E, Splenic marginal-zone lymphoma: a distinct clinical and pathological entitiy. Lancet Oncol 2003;4:95-103
   PubMed Web of Science ®Google Scholar
• Magagnoli M, Balzarotti M, Castagna L, Idiopathic thrombocytopenic purpura and splenic marginal-zone B-cell lymphoma: a causal correlation? Leuk Lymphoma 2003;44:1639-40
   PubMed Web of Science ®Google Scholar
• Sakalli H, Akcali Z, Kayaselcuk F, MALTOMA presenting with thrombocytopenia. Am J Clin Oncol 2005;28:321-2
   PubMed Web of Science ®Google Scholar
• Bachmeyer C, Audouin J, Bouillot JL, Immunie thrombocytopenia purpura as the presenting feature of gastric MALT lymohoma. Am J Gastroenterol 2000;95:1599-600
   PubMed Web of Science ®Google Scholar
• Figueroa M, Gehlsen J, Hammond D, Combination chemotherapy in refractory immune thrombocytopenia purpura. N Engl J Med 1993;328:1226-9
   PubMed Web of Science ®Google Scholar
• Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin N Am 2009;23:1261-74
   PubMed Web of Science ®Google Scholar
• Anastasiadis A, Margaritis D, Kotsianidis I, Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma – successful treatment with rituximab: a case report. Cases J 2009;18:6913
   Google Scholar
• Narra K, Borghaei H, Al-Saleem T, Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leuk Res 2006;30:109-14
   PubMed Web of Science ®Google Scholar
• Fodor A, Molnar MZ, Krenacs L, Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma. Pathol Oncol Res 2009;15:597-603
   PubMed Web of Science ®Google Scholar
• Yamazaki K. A case of splenic lymphoma with marked diffuse nodular fibrosis and calcification, complicated with severe autoimmune hemolytic anemia. J Submicrosc Cytol Pathol 2003;35:17-23
   PubMedGoogle Scholar
• Fabbri A, Gozzetti A, Lazzi S, Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma 2006;6:496-9
   PubMedGoogle Scholar
• Hauswirth AW, Skrabs C, Schutzinger C, Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica 2008;93:447-50
   PubMed Web of Science ®Google Scholar
• Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin N Am 2009;23:1261-74
   PubMed Web of Science ®Google Scholar
• Figueroa M, Ghelsen J, Hammond D, Combination chemotherapy in refractory immune thrombocytopenia purpura. N Engl J Med 1993;328:1226-9
   PubMed Web of Science ®Google Scholar
• Baudard M, Comte F, Conge AM, Importance of [18F] fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leuk Lymphoma 2007;48:381-8
   PubMed Web of Science ®Google Scholar
• Elsayed H, Hassan M, Nash J, Lung resection for treatment of idiopathic thrombocytopenic purpura associated with a pulmonary lymphoma. Ann Thorac Surg 2009;88:37-8
   Web of Science ®Google Scholar
• Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007;60:1378-83
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Trejo O, Garcia-Carrasco M, Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9
   PubMed Web of Science ®Google Scholar
• Elefsiniotis IS, Papatsimpas G, Liatsos GD, Atypical autoimmune polyglandular syndrome type 3 overlapped by chronic HCV infection resulting in carcinogenesis and fatal infection. South Med J 2008;101:756-8
   PubMed Web of Science ®Google Scholar
• Yildirim FE, Karaduman A, Hurmuz P, Symmetrical primary cutaneous marginal zone lymphoma associated with rheumatoid arthritis. J Cutan Pathol 2010;37:600-4
   PubMed Web of Science ®Google Scholar
• Burg G, Kerl H, Przybilla B, Some statistical data, diagnosis, and staging of cutaneous B-cell lymphomas. J Dermatol Surg Oncol 1984;10:256-62
   PubMedGoogle Scholar
• Bradford PT, Devesa SS, Anderson WF, Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064-73
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85
   PubMed Web of Science ®Google Scholar
• Adamidis KN, Metaxtos G, Hadjiconstantinou V. Splenic marginal lymphoma and glomerulonephritis: a case report and review of the literature. Ren Fail 2010;32:281-5
   PubMed Web of Science ®Google Scholar
• Tektonidou MG. MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. Lupus 2010;19:1243-5
   PubMed Web of Science ®Google Scholar
• Shimizu K, Yoshida J, Kakegawa S, Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol 2010;5:117-21
   PubMed Web of Science ®Google Scholar
• Giroux Leprieur E, Antoine M, Gounant V, Association between thymic MALT lymphoma and Sjogren's syndrome. Rev Pneumol Clin 2009;65:108-12; [article in French]
   PubMed Web of Science ®Google Scholar
• Kraemer DM, Weissinger F, Reimer P, Female patient with a history of Hashimoto's thyroiditis, diagnosed with MALT lymphoma of both breasts. Onkologie 2003;26:277-80
   PubMedGoogle Scholar
• Stokes MB, Wood B. Alpers ChE. Membranoproliferative glomerulonephritis associated with low grade B cell lymphoma presenting in the kidney. Clin Nephrol 2002;57:303-9
   PubMed Web of Science ®Google Scholar
• Ye MQ, Suriawinata A, Black C, Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a patient with primary biliary cirrhosis. Arch Pathol Lab Med 2000;124:604-8
   PubMed Web of Science ®Google Scholar
• Hahn JS, Kim C, Min YH, Non-Hodgkin's lymphoma & primary biliary cirrhosis with Sjogren's syndrome. Yonsei Med J 2001;42:258-63
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, IDEC-C2B8 (Rituximab) antiCD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6:195-7
   PubMedGoogle Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, Treatment of patients with low-grade B-cell lymphoma with the combination of anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Conconi A, Martinelli G, Thieblemont C, Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-5
   PubMed Web of Science ®Google Scholar
• Voog E, Morschhauser F, Solal-Celigny P. Correspondence: neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-4
   PubMed Web of Science ®Google Scholar
• Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 22 Nov 2010; [Epub ahead of print]
   Web of Science ®Google Scholar
• Salar A, Domingo-Domenech E, Estany C, Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-17
   PubMed Web of Science ®Google Scholar
• Brown JR, Friedberg JW, Feng Y, A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009;145:741-8
   PubMed Web of Science ®Google Scholar
• Peinert S, Carney D, Prince HM, Fludarabine combinations for patients with advanced marginal zone lymphomas–best treatment option or too toxic? Br J Haematol 2009;146:685-6
   PubMed Web of Science ®Google Scholar
• Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999;41:145-51
   PubMedGoogle Scholar
• Keating MJ, O'Brien S, Lerner S, Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as intial therapy. Blood 1998;92:1165-71
   PubMed Web of Science ®Google Scholar
• Dearden C, Wade R, Else M, The prognostic significance of a positive direct antigloblin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-6
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice. Expert Opin Pharmacother 2008;9:1-14
   PubMed Web of Science ®Google Scholar
• Wohrer S, Troch M, Zwerina J, Influence of rituximab, cyclophosphamide, doxyrubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 2007;18:647-51
   PubMed Web of Science ®Google Scholar